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Abstract
Background: Palpitations and pre-syncope are together responsible for 300,000 annual Emergency Department
(ED) attendances in the United Kingdom (UK). Diagnosis of the underlying rhythm is difficult as many patients are
fully recovered on ED arrival; and examination and presenting electrocardiogram (ECG) are commonly normal. The
only way to establish the underlying heart rhythm is to capture an ECG during symptoms. Recent technology
advances have led to several novel ECG monitoring devices appearing on the market. This trial aims to compare
the symptomatic rhythm detection rate at 90 days of one such smart phone-based event recorder (AliveCor Heart
Monitor and AliveECG) with standard care for participants presenting to the ED with palpitations and pre-syncope
and no obvious cause in the ED.
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Methods/Design: This is a multi-centre hospital ED / Acute Medical Unit (AMU) open label, randomised controlled
trial. Participants will be recruited in 10 tertiary and district general hospitals in the UK. Participants aged ≥ 16 years
presenting with an episode of palpitations or pre-syncope with no obvious cause and whose underlying ECG
rhythm during these episodes remains undiagnosed after clinical assessment will be included. Participants will be
randomised to either: (1) the intervention arm, standard care plus the use of a smart phone-based event recorder;
or (2) the control arm, standard care. Primary endpoint will be symptomatic rhythm detection rate at 90 days. A
number of secondary clinical, process and cost-effectiveness endpoints will be collected and analysed. Analysis will
be on an intention-to-treat basis.
Discussion: The Investigation of Palpitations in the ED (IPED) study aims to recruit 242 participants across 10
hospital sites. It will be the first study to investigate the ability of a smart phone-based event recorder to detect
symptomatic cardiac rhythms compared to standard care for ED patients with palpitations and pre-syncope with
no obvious cause in the ED. This smart phone event recorder will allow ED patients who have presented with
palpitations or pre-syncope to record their ECG tracing if they have a further episode and may increase the rate of
underlying rhythm diagnosis.
Trial registration: ClinicalTrials.gov, NCT02783898. Registered on 26 May 2016.
Keywords: Ambulatory electrocardiography monitoring, Cardiac arrhythmias, Palpitations, Pre-syncope
Background
Palpitations (the noticeable pounding, fluttering or ir-
regular beating of the heart) and pre-syncope (the sud-
den onset of a sense of impending loss of consciousness)
are together responsible for 1.0% of Emergency Depart-
ment (ED) visits (300,000 annual ED attendances in the
UK) [1, 2]. They are less likely to be due to serious
arrhythmia than syncope (sudden onset of brief loss of
consciousness) and are more likely due to conditions
such as atrial fibrillation (AF) and supraventricular
tachycardia (SVT). Patients suffering syncope lose con-
sciousness during the episode, meaning patient-activated
ECG recorders are not suitable for this population.
Diagnosis of the underlying rhythm is difficult as many
patients are fully recovered on ED arrival and examin-
ation and presenting electrocardiogram (ECG) are com-
monly normal. Once captured, the symptomatic rhythm
underlying many episodes (about 9/10) is found to be
due to benign causes such normal sinus rhythm, sinus
tachycardia or frequent ectopics (extra or skipped heart
beats) [3]. However, around 1/10 patients do have a car-
diac arrhythmia as their symptomatic rhythm [3].
The only way to establish the underlying heart
rhythm is to capture an ECG during symptoms. Many
patients go for years without diagnosis due to the dif-
ficulty in capturing the underlying heart rhythm. Rec-
ommended first line investigation of 12-lead ECG [4]
and conventional ambulatory monitoring (Holter or
event monitoring) [5, 6] are of limited efficacy due to
the infrequency of symptoms in many patients [5, 7–
10]. Most patients are discharged from the ED and
asked to represent or call an ambulance should they
get further symptoms in the hope of increasing the
chances of capturing the episode on a standard
12-lead ECG. In one US study, the admission rate for
this patient group was 24.6% [2].
If patients are referred to cardiology services for as-
sessment, investigation usually starts with a Holter
monitor but non-compliance and lack of extended mon-
itoring reduces diagnostic yield to < 20% [11]. Trad-
itional event recorders, external continuous loop
recorders and implantable loop recorders are expensive
and not recommended for a patient group who rarely
have malignant arrhythmias and may have prolonged pe-
riods between episodes.
Recent technology advances have led to several novel
ECG monitoring devices appearing on the market. The
pocket sized AliveCor Heart Monitor and AliveECG
phone/tablet app is a monitoring device that requires
the patient to trigger the ECG recording. It is available
for both Apple and Android mobile and tablet operating
systems and was CE marked in January 2015 [12]. With
minimal training, two fingers from each hand are placed
on the monitor (which can be connected to the back of
a smart phone) for 30 s to take an ECG recording, which
is transmitted wirelessly to the app, analysed and syn-
chronised to an encrypted server. The patient can then
alert their healthcare professional to allow their ECG to
be viewed securely [12].
The device is supported for clinical use by a National
Institute for Health and Care Excellence (NICE) technol-
ogy appraisal [12] and was initially developed for detect-
ing AF, for which the automatic diagnostic algorithm has
excellent sensitivity (96.6%) and specificity (94%) for cor-
rectly interpreting AF versus normal sinus rhythm [13].
The Arrhythmia Alliance [12] distributed AliveCor
Heart Monitors to 1500 people of all ages. Only one
returned their monitor because it caused them to worry
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and check their heart rate too often. Of recordings, 26%
showed a previously undetected arrhythmia and 5% were
advised to see their doctor urgently. They reported that
the AliveCor Monitor was ‘easy for people of all ages to
use, and could save money for the NHS when compared
with the cost of standard NHS ECG recordings.’ Older
people were also noted to be regular users of mobile tech-
nology and gave positive feedback about the system [12].
This is supported by previous work from our group [14].
There have been several studies investigating the use
of smart phone-based event recorders including Alive-
Cor for population screening for AF in various settings
[15–19] and feasibility for other rhythm disorders [3,
20]. While AliveCor has now undergone assessment
against conventional care for AF detection [21], it has
yet to be assessed against standard care for the broader
investigation of palpitations and arrhythmia assessment.
There have been no studies in an acute or ED popula-
tion, where large numbers of patients present [2].
We believe this smart phone event recorder will allow
ED patients who have presented with palpitations or
pre-syncope to record their ECG tracings if they have
further episodes, increasing the rate of underlying
rhythm diagnosis. If the patient only records benign
symptomatic rhythms then they can be reassured, given
advice about managing the episodes when they occur
and can be discharged from further investigation. Pa-




1. To compare the symptomatic rhythm detection rate
at 90 days of a smart phone-based event recorder
(AliveCor Monitor) compared to standard care for
participants presenting to the ED with palpitations
and pre-syncope with no obvious cause in the ED.
A ‘symptomatic rhythm’ will be any ECG rhythm re-
corded during an episode of palpitations or pre-syncope.
This can be either via the AliveCor Heart Monitor ECG
or through standard care. Any ECG recorded through
the AliveCor Heart Monitor ECG and sent to the study
team by the participant will be defined as symptomatic.
Secondary aims
1. To investigate the symptomatic rhythm detection
rate for cardiac arrhythmia detection at 90 days of a
smart phone-based event recorder compared to
standard care for participants presenting to the ED
with palpitations and pre-syncope.
2. To compare the time to detection of symptomatic
rhythm versus standard care.
3. To compare the time to detection of cardiac
arrhythmia (rhythm that is not sinus rhythm/sinus
tachycardia/ectopic beats) versus standard care.
4. To compare the number of participants treated or
(planned for treatment) for cardiac arrhythmia
versus standard care.
5. To investigate participant satisfaction and monitor
compliance.
6. To compare the cost of symptomatic rhythm
detection at 90 days of a smart phone-based event
recorder compared to standard care for participants
presenting to the ED with palpitations and pre-
syncope.
7. To compare serious outcomes at 90 days (all cause
death and major adverse cardiac events [MACE] =
myocardial infarction, life-threatening arrhythmia,
insertion of a pacemaker or internal cardiac defibril-
lator, insertion of pacing wire) in participants using




This is a multi-centre hospital ED / AMU open label,
randomised controlled trial of participants aged ≥ 16
years presenting with an episode of palpitations or
pre-syncope and whose underlying ECG rhythm during
these episodes remains undiagnosed after ED assess-
ment. Participants will be followed up at 90 days using
hospital records, contacting participant GP and also by
contacting the participants themselves. This study is ex-
pected to take around 18months to complete from first
participant recruited to last participants’ 90-day
follow-up.
Setting
EDs and AMUs of 10 tertiary and district general hospi-
tals in the UK.
Primary endpoint
1. Symptomatic rhythm detection rate of a smart
phone-based event recorder for symptomatic
rhythm detection at 90 days versus standard care.
Secondary endpoints
1. Symptomatic rhythm detection rate of a smart
phone-based event recorder for cardiac arrhythmia
detection at 90 days versus standard care.
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2. Time to detection of symptomatic rhythm using a
smart phone-based event recorder versus standard
care.
3. Time to detection of symptomatic cardiac
arrhythmia (rhythm that is not sinus rhythm/sinus
tachycardia/ectopic beats) using a smart phone-
based event recorder versus standard care.
4. Number of participants treated or (planned for
treatment) for cardiac arrhythmia in participants
using a smart phone-based event recorder versus
standard care.
5. Participant satisfaction and monitor compliance.
6. Cost-effectiveness analysis.
7. Serious outcomes at 90 days: all cause death and
MACE (myocardial infarction, life-threatening
arrhythmia, insertion of a pacemaker or internal
cardiac defibrillator, insertion of pacing wire).
Population
A total of 242 consecutive participants aged ≥ 16 years
presenting with an episode of palpitations or pre-syncope
and whose underlying ECG rhythm during these episodes
remains undiagnosed after ED assessment shall be re-
cruited into the study. Recruitment will last around 15
months.
Inclusion criteria
1. Participant aged ≥ 16 years;
2. Participant presenting with an episode of
palpitations or pre-syncope with no obvious cause;
3. Participant’s underlying ECG rhythm during these
episodes remains undiagnosed after clinical
assessment.
Exclusion criteria
1. Prior diagnostic ECG;
2. Palpitations or pre-syncope present during an ad-
mission ECG;
3. Frequent episodes (i.e. at least once a day);
4. Participants aged < 16 years;
5. Previous participation in the study;
6. Alcohol / illicit drugs / seizure / stroke / transient
ischemic attack / head trauma / hypoglycaemia as
presumptive cause;
7. Inability or unwilling to give informed consent;
8. Participants with recent (i.e. within three months)
myocardial infarction, severe heart failure (NYHA
class 4) or unstable angina;
9. Participants unwilling or unable to use the AliveCor
Heart Monitor and AliveECG app;
10. Participants without a compatible smart phone or
tablet;
11. Participants with cardiac pacemakers or other
implanted electronic devices;
12. No telephone number for follow-up;
13. Participant in custody.
Participant selection and enrolment
The research team, where it is locally agreed that they
are part of the clinical care team, will screen and identify
potential participants using triage information and clin-
ical or electronic records in the ED or the AMU. In this
case, it is anticipated they would identify potential par-
ticipants and make the first approach. Any member of
the clinical team who has received general and trial spe-
cific training and is on the delegation log may also iden-
tify participants in this way. If the research team are not
considered to be part of the direct care team locally, ac-
tivities carried out before consent (including identifica-
tion) will be carried out by a member of the direct care
team. Where the researcher is not considered to be part
of the care team, the researcher should ask a member of
the direct care team to identify suitable participants and
ask permission from the participant to be approached by
the researcher to discuss participation.
If the potentially eligible participant fulfils the study
eligibility criteria, a member of the study research team
(or direct care clinician if suitably trained) will take writ-
ten consent. The participant is assessed by the direct
care team to establish if he/she is competent and has
capacity to consent. This assessment will be documented
in the medical notes, i.e. this participant is eligible and
capable of providing written informed consent. Partici-
pants lacking capacity who are unable to provide con-
sent will not be approached to take part in the study.
The participant (and, if present and appropriate, their
accompanying relative) will be given a Participant Infor-
mation Sheet, which will explain the aims of the study
and the potential risks and benefits of the study proce-
dures/tests. The participant will be given enough time to
consider the study and ask questions regarding their par-
ticipation in the study. For some participants this could
be as much as 1 h but for others may only be 10–15
min. If the participant agrees, informed consent will be
confirmed with a signature on the study consent form.
The original consent form will be filed in the Investiga-
tor Site File (ISF), the participant will receive a copy of
this document and a copy will be filed in the partici-
pant’s medical notes. Potential, eligible participants who
are able to express their consent and able to complete
the consent form will be asked to provide written con-
sent. The recruiting direct care clinician or member of
the research team will do this. A witness will sign to
confirm that all the study information was given and the
participant consented to taking part in the study for
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participants who are able to express their consent but
unable to sign.
Screening for eligibility
There is a requirement to ensure Good Clinical Practice
for published studies and to include a Consort diagram
[22] of numbers of participants with the study condition
during the study period who for one reason or another
were not enrolled in the study. In order to determine
the number of eligible but not recruited participants
during the study period, the ED patient record of all po-
tentially eligible participants will be interrogated by a
member of the study research team (if part of the partic-
ipant’s direct care team). An anonymised log will be kept
for patients who were screened for the study and those
who were subsequently found to be ineligible or who
were not recruited. Non-recruited but potentially eligible
participants will be identified by a daily search of all
acute patient admissions records to assess for potential
selection/recruitment bias. Ineligible patients will not be
recorded.
Randomisation
Participants will be equally distributed between the two
study arms with 121 participants in each arm. In order
that participants are randomly allocated to a treatment
group, while maintaining a balance across the treatment
groups, randomisation will be by permuted block ran-
domisation. Randomisation codes will be generated;
blinded envelopes will be prepared and labelled in ac-
cordance with the randomisation list for each participat-
ing site. Permuted random block sizes of 30 will be used.
Randomisation codes will be held by each recruiting re-
search team in an accessible area. Participants eligible
for inclusion should be randomised by taking the next
lowest consecutively numbered envelope.
Treatment allocation
Participants will be allocated either to: (1) the interven-
tion arm, consisting of standard care plus the use of a
smart phone-based event recorder; or (2) the control
arm, consisting of standard care, depending on the
group allocated in the study envelope. If a participant
wishes to withdraw from the study, they will be re-
moved. We will establish whether they consent to allow
the use of all data collected up to the date of removal.
Study interventions
Figure 1 details the Trial Assessment Schedule. Poten-
tially eligible ED and AMU participants will be identified
and assessed for study inclusion by the attending clin-
ician. Written consent will be taken and participants will
have a case report form (CRF) completed and a 12-lead
ECG taken if not already performed by the clinical team.
All intervention arm participants will be given an Alive-
Cor Heart Monitor and trained in the use of the device
and app in the ED or AMU by the research team. Con-
trol arm participants will receive no other research inter-
vention. Participants in both groups will be admitted,
referred or discharged by the treating clinician according
to current local hospital protocols. Ongoing treatment
and investigation in both groups will be according to
current local hospital protocols. Participants in both
groups will be followed up at 90 days through hospital
record systems (paper or electronic depending on local
policy), GP records and by telephone by the local study
team. Participants will also be asked to complete a
standardised written questionnaire and will receive a
follow-up telephone call from the local study team
enquiring about symptoms and contact with medical
services. Participants will also be asked about satisfaction
and compliance with the heart monitor.
Participants allocated to the intervention arm may be
contacted by telephone by the local research team
shortly after randomisation in the event of them requir-
ing further training or setting up of the device. For ex-
ample, this may be necessary if a participant does not
have their app store password with them in the ED or
AMU. If a local electronic patient record system is avail-
able, then a research alert will be placed on this stating
that the participant has consented to be part of the IPED
study to avoid inadvertent unauthorised co-enrolment
with other research studies.
If a participant allocated to the intervention arm gets
an episode of palpitations or pre-syncope and is able to
record an AliveCor Heart Monitor ECG during the epi-
sode, the participant will email the ECG recorded by the
AliveCor app directly to the coordinating Edinburgh re-
search team at a convenient time to the participant and
to a secure nhs.net email address. This email includes a
PDF attachment of the ECG tracing along with the par-
ticipant’s AliveCor app login (which will be their IPED
study number - no identifiable participant data will leave
the local site, only the participants email address and
IPED study number will appear), time and date of
recording, and ECG recording. AliveCor collects
non-sensitive usage data through a third-party service
called Mixpanel. Participants will not be asked to send
their ECGs to AliveCor directly for analysis. The Alive-
Cor app rhythm analysis algorithm will automatically re-
port any ECG recorded by the AliveCor app as Normal,
Atrial Fibrillation or Unclassified.
The duty Consultant Emergency Physician at the co-
ordinating Edinburgh centre along with a trial team
Emergency Physician will review the ECG and will con-
tact the local study team to arrange follow-up if re-
quired. In cases of disagreement, the central cardiology
team were contacted for further opinion. If specialist
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follow-up of the ECG tracing is not required then the
local study team will write to the participant informing
them of this (Patient ECG follow-up letter normal v2.0
24,082,016 and Patient ECG follow-up letter abnormal
v2.0 24,082,016) and asking them to arrange follow-up
with their general practitioner who will be contacted
with the report (GP Follow up Letter v2.0 24,082,016).
The participant and GP will not be contacted further
should participants record other similar ECGs that simi-
larly do not require specialist follow-up.
The local study team will alert the participant immedi-
ately by telephone and refer them urgently to their local
ED or cardiac electrophysiology service (as per local
protocol) if the participant records a serious cardiac
arrhythmia during the study period, i.e.:
 ventricular fibrillation (VF);
 ventricular tachycardia (VT) (it will be assumed that
this is symptomatic given the participant has chosen
to record an ECG during the episode);
 complete or third-degree heart block;
 second-degree heart block type II (it will be assumed
that this is symptomatic given the participant has
chosen to record an ECG during the episode);
 pause > 6 s;
 symptomatic bradycardia < 40 beats per minute.
Participant follow-up
Participants will be asked to log any symptoms along
with the time and date, type of symptom and whether
they were able to record an ECG during the symptoms,
in a participant symptom diary. They will return this
diary to the local research team along with the partici-
pant satisfaction and compliance questionnaire, and
Fig. 1 Trial assessment schedule
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smart phone-based event recorder at the end of the 90
days in a pre-paid, stamped, addressed envelope. Partici-
pants will be phoned at 90 days by the local study team
to remind them to complete the participant satisfaction
and compliance questionnaire and to return this to the
local study team with the symptom diary and smart
phone-based event recorder. The compliance question-
naire is designed to capture whether participants had
the device with them and were able to record a heart
tracing during symptoms. This will be entered onto the
study database by the local study team.
Data collection
Participants will have a CRF completed during index
hospitalisation, comprising demographic, historical and
examination characteristics. An ECG will also be taken
and stored. Participant contact details will also be con-
firmed including a telephone number and email address.
Once a participant has been randomised, the baseline
CRF will be sent to the local study team office. The in-
formation on the CRF will be entered into a specially de-
signed password protected online accessed secure
database (REDCAP; http://www.project-redcap.org), the
server of which is held within the University of Edin-
burgh. No participant identifiable information will leave
the recruiting NHS hospital or be entered onto RED-
CAP. Participants will be identified on REDCAP by
study number alone.
Statistics and sample size calculation
Using a symptomatic rhythm detection rate at 90 days of
25% [12] versus standard care (10%), we estimate 110
participants in each group would have 80% power to de-
termine a 15% improvement in symptomatic rhythm de-
tection. We will recruit an extra 10% in each arm to
allow for drop-out (i.e. 121 participants in each arm).
Our ED sees around 500 eligible participants a year. As-
suming a 50% recruitment rate, we estimate we will need
to recruit for 15 months.
Proposed analysis
Descriptive analysis of participant characteristics shall be
presented split by study arm. Baseline to 90 day change
in diagnostic yield between the two study arms will be
analysed using two sample t-tests or non-parametric
equivalent as appropriate. Log-rank tests and Kaplan–
Meier curves shall be used to examine if the smartphone
recorder has an effect on detecting symptomatic rhythm
and cardiac arrhythmia separately up to 90 days versus
standard care. Categorical variables will be compared
using a χ2 test (and χ2 test for trend if appropriate). All
participants will be analysed on an intention to treat
basis.
Study conduct; protocol amendments
Any changes in research activity, except those necessary
to remove an apparent, immediate hazard to the partici-
pant in the case of an urgent safety measure, must be
reviewed and approved by the Chief Investigator.
Amendments to the protocol must be submitted in writ-
ing to the appropriate REC and local R&D for approval
before participants being enrolled into an amended
protocol. A Data Monitoring Committee has not been
established.
Protocol violations and deviations
Prospective protocol deviations, i.e. protocol waivers,
will not be approved by the sponsor and therefore will
not be implemented, except where necessary to elimin-
ate an immediate hazard to study participants. If this ne-
cessitates a subsequent protocol amendment, this should
be submitted to the REC and local R&D for review and
approval if appropriate. Protocol deviations will be re-
corded in a protocol deviation log and logs will be sub-
mitted to the sponsors every three months. Each
protocol violation will be reported to the sponsor within
24 h of becoming aware of the violation.
Reporting, publication and notification of results
Ownership of the data arising from this study resides
with the study team. On completion of the study, the
study data will be analysed and tabulated, and a clinical
study report will be prepared in accordance with ICH
guidelines.
The results of our research will be disseminated in the
following ways:
1. Summary disseminated to NHS Lothian
communication systems including EMERGE intra-
and Internet sites and all participating sites;
2. A media summary;
3. Presentation at local and national educational,
clinical and research meetings and international
research meetings;
4. Publication in peer-reviewed journals;
5. Research report disseminated to NHS Lothian
R&D, NHS Research Scotland, and CHSS.
The clinical study report will be used for publication
and presentation at scientific meetings. Investigators
have the right to publish orally or in writing the results
of the study.
Discussion
The IPED study will recruit 242 participants across 10
hospital sites. It will be the first study to investigate the
ability of a smart phone-based event recorder to detect
symptomatic cardiac rhythms compared to standard care
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for ED patients with palpitations and pre-syncope with
no obvious cause in the ED. This smart phone event re-
corder will allow ED patients who have presented with
palpitations or pre-syncope to record their ECG tracing
if they have a further episode and may increase the rate
of underlying rhythm diagnosis.
Trial status
The trial opened to recruitment in July 2016 in Edin-
burgh and by early 2017 there were 10 UK sites partici-
pating. Recruitment is anticipated to run until December
2017 with trial completion by mid 2018. As of Novem-
ber 2017, 88% of the study population was recruited.
This is protocol version number 3.0, dated 09 October
2016.
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